Artiva Biotherapeutics Ends AlloNK Program, Shares Slide
Artiva Biotherapeutics pulled the plug on its lead development candidate, AlloNK, and said it would explore alternatives to maximize shareholder value. Shares fell sharply Tuesday.
By Colin KellaherArtiva Biotherapeutics shares fell sharply Tuesday after the clinical-stage biotechnology company pulled the plug on lead development candidate AlloNK and said it would explore alternatives to maximize shareholder value.Shares of the San Diego company were recently changing hands a…